The Epstein-Barr virus (EBV) glycoproteins H (gH) and L (gL) form a heterodimer essential for viral entry into host cells. This complex mediates membrane fusion in cooperation with other viral glycoproteins, enabling EBV to infect both B lymphocytes and epithelial cells. Antibodies targeting gH/gL can block this fusion process, thereby neutralizing infection. Such antibodies are valuable tools for studying EBV pathogenesis, evaluating vaccine candidates, and developing diagnostic assays. Because gH/gL are conserved and exposed on the viral envelope, they elicit strong immune responses, making anti-gH/gL antibodies important in both research and potential therapeutic applications. - Antikörper
Tag:
Human IgG1 | Human Kappa
Puffer:
PBS, pH7.4
Reinheit:
0.95
Formulierung:
Powder
Target-Kategorie:
Glycoprotein H & Glycoprotein L/gH & gL (EBV)
Immobilized Epstein-Barr virus Glycoprotein H&Glycoprotein L Heterodimer Protein, Twin-Strep&His Tag (Cat. No. GHL-E5283) at 1 µg/mL (100 µL/well) can bind Monoclonal Anti-Epstein-Bar Virus (EBV) gH&gL Antibody, Human IgG1 (8C5) (Cat. No. GHL-MY2403) with a linear range of 0.05-2 ng/mL (QC tested).
Monoclonal Anti-Epstein-Bar Virus (EBV) gH&gL Antibody, Human IgG1 (8C5) on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 0.95.
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten